GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)

被引：1
|
作者：
Yang, M. [1 ]
Tan, E. C. [1 ]
Chen, Y. [2 ]
机构：
[1] Natl Taiwan Univ, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.284
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN4
引用
收藏
页码：A885 / A885
页数：1
相关论文
共 50 条
  • [1] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [2] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [3] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [4] Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan
    Hsia, T.
    Chang, G.
    Chen, Y.
    Lin, M.
    Su, W.
    Tsai, C.
    Tsai, C.
    Yang, L.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375
  • [5] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    [J]. DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [6] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [7] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    [J]. LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [8] Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy
    Fiala, O.
    Pesek, M.
    Finek, J.
    Krejci, J.
    Bortlicek, Z.
    Benesova, L.
    Minarik, M.
    [J]. NEOPLASMA, 2013, 60 (02) : 129 - 134
  • [9] Erlotinib in non-small cell lung cancer (NSCLC) in Germany - A cost-saving second-line treatment option?
    Gabriel, A.
    Pirk, O.
    Kotowa, W.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A278 - A278
  • [10] Second-line chemotherapy for non-small cell lung cancer
    De Marinis, F.
    De Santis, S.
    De Petris, L.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : V68 - V71
12345